Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying participants with active systemic lupus erythematosus SLE, including those with lupus nephritis, who have not responded adequately to glucocorticoids and at least two immunosuppressant therapies. The aim is to characterize the effectiveness and safety of current standard of care treatments for this condition. This observational study focuses on understanding how these treatments work in real-world settings for patients with active disease. Participants receive treatments based on the current standard of care according to product guidelines, including biologic therapies among other immunosuppressants. The study specifically includes those with active disease confirmed by clinical assessments and positive autoantibodies. Participants with lupus nephritis must have had a recent renal biopsy showing specific active kidney involvement. Treatment and observation continue over several years to evaluate long-term outcomes. During the study, participants undergo evaluations at regular intervals up to 60 months. Researchers assess disease remission, kidney function, disease activity scores, flare frequency, and patient-reported fatigue. Data collection involves clinical assessments, laboratory tests, and questionnaires to measure treatment response and safety. This long-term follow-up provides insight into how well patients maintain remission and respond to standard therapies over time.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease CKD and metabolic acidosis. This phase 3 study compares veverimer against a placebo to better understand its impact on these conditions. The study is sponsored by Renibus Therapeutics, Inc. and uses a randomized, double-blind, placebo-controlled design to ensure reliable results. Participants are randomly assigned to receive either 9 g of veverimer twice daily or a placebo twice daily. The study lasts up to 168 days, during which the effects of the treatments on serum bicarbonate levels and physical performance, specifically the Sit-to-Stand 5 times test, are assessed. The trial also monitors safety and tolerability through treatment-emergent adverse events throughout the study period. During the study, participants will have regular visits from screening through Day 168 where various assessments take place. These include measuring serum bicarbonate concentration, physical performance tests, frailty and muscle mass evaluations, and safety checks. Participants are expected to maintain consistent dietary habits and stable doses of any oral alkali therapies during the trial. The total length of participation extends through the 168-day treatment and evaluation period.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of LUPKYNIS combined with belimumab, obinutuzumab, or anifrolumab in adults with lupus nephritis LN. The study focuses on how well these combinations induce a rapid kidney response in patients diagnosed with LN, a condition affecting kidney health. It is a phase 4 clinical trial sponsored by Aurinia Pharmaceuticals Inc. that assesses treatment approaches for this condition. Participants will receive LUPKYNIS along with one of the biologic agents belimumab, obinutuzumab, or anifrolumab. In addition, all patients will be treated with a mycophenolic acid analog MPAA, such as mycophenolate mofetil or mycophenolic acid, and corticosteroids like prednisone or an equivalent. The biologic treatment schedules vary depending on the specific drug, with some patients already receiving treatment before the study starts or beginning it at the start of the trial. During the study, participants will be monitored for kidney response over 24 weeks, including complete and partial renal responses. Researchers will assess safety by tracking treatment-emergent adverse events up to 28 weeks. Other assessments include measuring changes in kidney-related antibodies and complement levels at baseline, 12 weeks, and 24 weeks. The total participation duration extends to about 28 weeks, during which various evaluations, laboratory tests, and safety monitoring will occur to understand treatment effects and patient outcomes.